

REQUEST FOR KRAS MUTATION TESTING

Molecular Pathology Service

Pathology, Level 6, Ninewells Hospital, Dundee, DD1 9SY

Phone/FAX: Tel 01382 496261 / Fax 01382 496382

E-mail: Tay-UHB.moleculargenetics@nhs.net



Laboratory
Reference No: 2282



PATIENT DETAILS *(printed label preferred)*

Family Name:

First Name(s):

DOB: Sex: M / F

CHI Number:

Hospital Number:

Address:

Postcode:

REQUESTING CONSULTANT *(ONCOLOGIST)*

Consultant Name:

Address for Report:

Date of Request:

Phone: Fax:

Contact / Address for Invoice:

CLINICAL DETAILS *(TO BE COMPLETED BY REQUESTING CONSULTANT)*

Does the patient meet SMC (543/09) criteria: Yes / No

Is the patient being considered for 1st line treatment: Yes / No

Is the patient being considered for 2nd / 3rd line treatment: Yes / No

Other reason for referral (please state)

SPECIMEN DETAILS *(TO BE COMPLETED BY CONSULTANT PATHOLOGIST)*

Name of Pathologist:

Address of Pathology Department *(for return of blocks)*:

Block Reference Number:

A paraffin block of suitable tumour material and an accompanying H&E slide should be sent to the Molecular Pathology Service at the address above. Samples should be dispatched as soon as possible since treatment is dependent on the results of KRAS testing.

The block and copy of the Molecular Genetic test report will be returned to the referring Pathology department as soon as analysis is complete.

MOLECULAR PATHOLOGY LAB USE ONLY

Block Received by and Date:

Pathology Sample Number:

Consultant Pathologist:

Please estimate what proportion of the tissue section is tumour: %

Date sections sent to Molecular Genetics:

MOLECULAR GENETIC LAB USE ONLY

Sections Received by and Date:

MG Number

Please note unless otherwise requested, following testing, all DNA samples will be stored in the laboratory.

Incomplete or illegible forms will cause delay or rejection of samples.

Guidance for Referring Samples for KRAS testing



Laboratory
Reference No: 2282



Molecular Pathology Service

Pathology, Level 6, Ninewells Hospital, Dundee, DD1 9SY

Phone/FAX: Tel 01382 496261 / Fax 01382 496382

E-mail: Tay-UHB.moleculargenetics@nhs.net

Consultant Oncologists and Other Requesting Consultants

Under Scottish Medical Consortium guidance, the determination of KRAS mutation status is a prerequisite for Cetuximab treatment. To initiate KRAS testing, Consultant Oncologists and other requesting Consultants should complete the following sections of the KRAS Mutation Testing Request Form:

- *Patient Details*
- *Requesting Consultant*
- *Clinical details*

Once these sections have been completed, the request form should be forwarded to the appropriate Pathology Department holding the tumour block.

Consultant Pathologists

You may be asked by a Consultant Oncologist or other Requesting Consultant to provide a tumour sample for KRAS testing in relation to Cetuximab therapy for metastatic colorectal cancer.

The request will be prompted by the receipt of a KRAS Mutation Testing request form, with the patient and clinical details already completed by the Requesting Consultant.

The Consultant Pathologist is requested to identify a tumour-rich block from the patient and complete the *Specimen Details* on the Request form. The tumour block, together with the completed Request form and an H&E-stained slide of tumour should be forwarded to the Molecular Pathology Service at the address above.

Only tumour samples accompanied by a completed Request form will be accepted by the Molecular Pathology Service for KRAS testing.

Once KRAS mutation testing has been completed, the tumour block will be returned to you together with a copy of the KRAS test report.

Please note unless otherwise requested, following testing, all DNA samples will be stored in the laboratory.

Cost of KRAS Testing

The total cost of KRAS testing is £188; this includes specimen receipt, preparation of tumour sections, estimation of the proportion of tumour and testing for mutations at codons 12, 13 and 61 of KRAS.

For an NHS Scotland patient who meets the SMC criteria for Cetuximab treatment, the cost of the KRAS test will be billed to the requesting hospital.

For NHS Scotland patients who do not meet the criteria, the cost of the test will be covered by Merck Serono.

Please confirm whether or not the patient meets the Scottish Medical Consortium (SMC) criteria for Cetuximab treatment on the KRAS Request Form.